| Adamis Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including opioid overdose, respiratory and inflammatory disease. Co.'s products and product candidates include: Symjepi (epinephrine) Injection 0.3mg for use in the treatment of acute allergic reactions, including anaphylaxis; SYMJEPI (epinephrine) Injection 0.15mg for use in the treatment of anaphylaxis for patients weighing 33 to 65 pounds; a naloxone injection product candidate ZIMHI for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-1000) for the treatment of asthma. The ADMP YTD return is shown above.
The YTD Return on the ADMP YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether ADMP YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ADMP YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.